Pro­teosta­sis shares zoom north as their cys­tic fi­bro­sis dou­blet caus­es a stir in small study -- trig­ger­ing an on­line brawl

Some­times it’s the small­est stud­ies that gain the biggest re­ac­tions from the in­vest­ment crowd that fol­lows biotech.

Case in point: Lit­tle Pro­teosta­sis Ther­a­peu­tics hit big-time pay dirt on Thurs­day, watch­ing its stock $PTI swoop up 448% on some in­trigu­ing ear­ly da­ta on a hand­ful of pa­tients suf­fer­ing from cys­tic fi­bro­sis.

Break­ing 21 pa­tients ho­mozy­gous for the F508del mu­ta­tion in­to var­i­ous dose groups for their CF dou­blet ther­a­py, re­searchers teased out some sig­nif­i­cant re­sults for the few peo­ple in the high dose co­hort that was evalu­able at the time of the Phase I cut­off for their read­out.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.